Insulin Use in Primary Care: Practice Challenges

Slides:



Advertisements
Similar presentations
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia.
Advertisements

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections.
Diabetes Update Part 2 of 3 Division of Endocrinology
Insulin Initiation With NovoMix30
What's New in Basal Insulin for Diabetes
Fig. 2. Change in (A) glycosylated hemoglobin (HbA1c) and (B) fasting plasma glucose (FPG). Group A: oral hypoglycemic agents (OHAs; sulfonylurea+metformin.
Fig. 1. Study flow chart. Group A: intensifying oral hypoglycemic agents (OHAs; sulfonylurea+metformin dose titration or fixed-dose combination added to.
Case-Based Examination of Treatment Options in Type 2 Diabetes Management.
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
Monitoring and Modifying Treatment in PAH
Applying Data to Practice
RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL
Special Consideration in Insulin Therapy
Faster-Acting Insulins
The role of metabolic surgery in the management of obesity and t2dm
New Patient-Friendly Options for Managing Insulin Dosing
Modern Strategies for Basal Insulin Use in T2D
Patient Case Discussions in T2D: What Intensification Plan Is Best?
Insulin/GLP-1 Agonist Combinations
Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence.
Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.
Insulin Intensification Strategies in Later-Stage Type 2 Diabetes Mellitus.
Agenda. Insulin Intensification Strategies: An Expert Perspective from Asia-Pacific.
How Early Should Basal Insulin Be Used in T2D Management?
Novel Concentrated Insulins: What Benefits and for Which Patients?
Updates Abound.
Working as a Team for Improved Patient Outcomes in Type 2 Diabetes
Examining CV Effects of Basal Insulin Therapy
What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?
Innovative Insulin Combinations: A New strategy for the Person With T2DM.
Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.
Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?
Emerging Basal Insulins for Diabetes
Sequential insulin strategies in type 2 diabetes.
Insights into Insulin Treatment Challenges: Real-World Evidence and Clinical Trial Data.
GLP-1 Receptor Agonists: How Early Is Appropriate?
Athena Philis-Tsimikas, MD  The American Journal of Medicine 
Novel Insulin Combinations: What Does the Primary Care Physician Need to Know?
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?
Early and Intensive T2D Management:
Insulin/GLP-1 Agonist Combinations
Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.
The Importance of Getting the Dose Right in HF
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
Average patient profile in terms of (A) previous therapy drug class and (B) complexity of previous regimen. Average patient profile in terms of (A) previous.
T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus
Simplifying Insulin Delivery for Better Patient Outcomes in T2D
Better Diabetes Control With Novel Basal Insulins
Individualizing Insulin Therapy in the Management of Type 2 Diabetes
Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?
Program. Basal Insulin in the Modern Era The CDE's Role in Improving Utilization and Outcomes.
Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.
Approach to starting and adjusting insulin in type 2 diabetes.
Advancements in Glucose Monitoring
Modern strategies for management of glycaemia in type 1 diabetes
COMBINATIONS AND COFORMULATIONS: THE FUTURE OF INSULIN THERAPY?
Improving Effective Basal Insulin Use in Clinical Practice
Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.
Patient Stories in PAH: Sequential Therapy in a FC II Patient
Kaplan-Meier plot of incident CVD according to the treatment group over a 4-year period following intensification of diabetes therapy. Kaplan-Meier plot.
Are All Novel Insulins Proven to Be Equally Safe?
Optimal Treatment of PAH
Emerging Combination Injectable Therapy A New Era in Diabetes Care
New Approaches for Type 2 Diabetes -- GLP-1 RAs Now and in the Future
Practical Strategies for Overcoming Emotional Barriers to Insulin Initiation in the Primary Care Setting.
Fixed-Ratio Combination Therapy in T2DM
Emerging Basal Insulins for Diabetes
The Elevated Role of GLP-1 RAs in Diabetes Management: Which Patients Should We Aim For?
Fresh perspectives ON BASAL Insulins in diabetes care
Presentation transcript:

Diabetes Challenges in Primary Care: How to Initiate and Intensify Insulin Therapy

Insulin Use in Primary Care: Practice Challenges

Agenda

ADA/EASD Recommendations for T2DM Management: When Is Insulin Use Indicated ?

Barriers to Initiation of Insulin Therapy

Triggers to Initiate Insulin in Primary Care

Insulin Regimens—3 Practical Steps

Basal Insulin Therapy

Initiation and Titration of Basal Insulin: Example—Degludec

Initiation and Titration of Basal Insulin: Example—Glargine

Insulin Optimization or Intensification: When, Why, How?

ADA/EASD Position Statement: Sequential Insulin Strategies in T2DM Management

Rationale for GLP-1 RA/Basal Insulin Combination

IDegLira Fixed-Ratio Combination: Change in HbA1c

Dosing Regimen of IDegLira Fixed-Ratio Combination (Once-Daily Pen SC Injection)

Conclusions

Abbreviations